Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647699 · ClinicalTrials.gov registry record · Phase 3
Corneal Collagen Cross-linking for Progressive Keratoconus
A Phase 3 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT00647699 is a Phase 3 study that has completed, run by Glaukos Corporation. The registered enrollment target is 147 participants.
The verdict
NCT00647699, a Phase 3 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
Interventions
- DRUG riboflavin ophthalmic solution
- DEVICE UVA Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647699
The ClinicalTrials.gov registry entry for NCT00647699 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which riboflavin ophthalmic solution is the first listed.
NCT00647699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647699 about?
NCT00647699 is a clinical study titled "Corneal Collagen Cross-linking for Progressive Keratoconus". Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
What is the current status of trial NCT00647699?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2007-12. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00647699?
The interventions under investigation include: riboflavin ophthalmic solution (DRUG), UVA Irradiation (DEVICE).
Who is sponsoring clinical trial NCT00647699?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.